Joerg H. Eckert

Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study

G. Feldman, F. Patalano, P. D’Andrea, 2016, International journal of chronic obstructive pulmonary disease.

Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study

G. Feldman, F. Patalano, P. D’Andrea, 2016, International journal of chronic obstructive pulmonary disease.

Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).

D. Mahler, A. Satti, A. Gifford, 2016, Respiratory medicine.

Long-term safety of glycopyrrolate : A randomized study in patients with moderate-to-severe COPD ( GEM 3 )

D. Mahler, A. Satti, A. Gifford, 2016 .

Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD: The GEM2 Study.

E. Kerwin, A. White, P. Korenblat, 2016, Chronic obstructive pulmonary diseases.

Chronic Obstructive Pulmonary Diseases : Journal of the COPD Foundation Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD : The GEM 2 Study

E. Kerwin, A. White, P. Korenblat, 2016 .

Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial

J. Wedzicha, G. Criner, M. Shinkai, 2023, American journal of respiratory and critical care medicine.